| First Author | Mohammad AH | Year | 2019 |
| Journal | Oncotarget | Volume | 10 |
| Issue | 48 | Pages | 4923-4936 |
| PubMed ID | 31452834 | Mgi Jnum | J:315777 |
| Mgi Id | MGI:6831273 | Doi | 10.18632/oncotarget.27075 |
| Citation | Mohammad AH, et al. (2019) V-ATPase-associated prorenin receptor is upregulated in prostate cancer after PTEN loss. Oncotarget 10(48):4923-4936 |
| abstractText | Phosphatase and tensin homolog (PTEN) tumor suppressor protein loss is common in prostate cancer (PCa). PTEN loss increases PI3K/Akt signaling, which promotes cell growth and survival. To find secreted biomarkers of PTEN loss, a proteomic screen was used to compare secretomes of cells with and without PTEN expression. We showed that PTEN downregulates Prorenin Receptor (PRR) expression and secretion of soluble Prorenin Receptor (sPRR) in PCa cells and in mouse. PRR is an accessory protein required for assembly of the vacuolar ATPase (V-ATPase) complex. V-ATPase is required for lysosomal acidification, amino acid sensing, efficient mechanistic target of Rapamycin complex 1 (mTORC1) activation, and beta-Catenin signaling. On PCa tissue microarrays, PRR expression displayed a positive correlation with Akt phosphorylation. Moreover, PRR expression was required for proliferation of PCa cells by maintaining V-ATPase function. Further, we provided evidence for a potential clinical role for PRR expression and sPRR concentration in differentiating low from high Gleason grade PCa. Overall, the current study unveils a mechanism by which PTEN can inhibit tumor growth. Lower levels of PRR result in attenuated V-ATPase activity and reduced PCa cell proliferation. |
